Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
32 hedge funds and large institutions have $18.1M invested in Catalyst Pharmaceutical in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 8 closing their positions.
300% more call options, than puts
Call options by funds: $12K | Put options by funds: $3K
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
28% more funds holding
Funds holding: 25 → 32 (+7)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
26% less capital invested
Capital invested by funds: $24.4M → $18.1M (-$6.28M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$485K |
| 2 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$314K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$303K |
| 4 |
State Street
Boston,
Massachusetts
|
+$95.4K |
| 5 |
CPA
Cowen Prime Advisors
New York
|
+$60.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$1.36M |
| 2 |
SC
Sophrosyne Capital
New York
|
-$732K |
| 3 |
Renaissance Technologies
New York
|
-$422K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$144K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$95K |
CPRX Hedge Fund Activity: Q4 2013 in Review
32 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2013, worth a combined $18.1M — down 26% from $24.4M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CPRX positions and 8 closed out — a net gain of 7 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $485K. The largest seller was EAM Investors, exiting entirely with an estimated $1.36M sold.
- 32 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2013, up from 25 in Q3 2013.
- Funds reported $18.1M of Catalyst Pharmaceutical stock for Q4 2013, down 26% quarter-over-quarter.
- 15 funds opened new Catalyst Pharmaceutical positions in Q4 2013 and 8 closed out, a net change of +7 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2013 was Vanguard Group, an estimated $485K added.
- The largest Catalyst Pharmaceutical seller in Q4 2013 was EAM Investors, an estimated $1.36M sold.
Based on aggregated 13F filings for Q4 2013.